Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-01-04
2011-01-04
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007100
Reexamination Certificate
active
07863249
ABSTRACT:
The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due toClostridium difficile(“C. difficile”),Clostridium perfringens(“C. perfringens”),Staphylococcusspecies, for example, methicillin-resistantStaphylococcus, orEnterococcusincluding Vancomycin-resistant enterococci.
REFERENCES:
patent: 3978211 (1976-08-01), Coronelli et al.
patent: 4918174 (1990-04-01), McAlpine et al.
patent: 5583115 (1996-12-01), McAlpine et al.
patent: 5767096 (1998-06-01), Hochlowski et al.
patent: 7378508 (2008-05-01), Chiu et al.
patent: 2006/0257981 (2006-11-01), Shue et al.
patent: 2007/0105791 (2007-05-01), Sears et al.
patent: 2007/0173462 (2007-07-01), Shue et al.
patent: 2007/0259949 (2007-11-01), Chiu et al.
patent: 2008/0269145 (2008-10-01), Shue et al.
patent: 2009/0163428 (2009-06-01), Chiu et al.
patent: 2010/0009925 (2010-01-01), Shue et al.
patent: 2010/0010076 (2010-01-01), Chiu et al.
patent: 2010/0035833 (2010-02-01), Ichikawa et al.
patent: 2010/0081800 (2010-04-01), Chiu et al.
patent: WO 96/35702 (1996-11-01), None
patent: WO 2004/014295 (2004-02-01), None
patent: WO 2005/112990 (2005-12-01), None
patent: WO 2006/085838 (2006-08-01), None
Remington: The Science and Practice of Pharmacy, published 2000 by Lippincott Williams and Wilkins, pp. 802-803.
Babakhani et al., “Narrow spectrum activity and low fecal protein binding of Opt-80 and its major hydrolysis metabolite (OP-1118)”, Program and Abstract of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, p. 212 (2007), XP008103008.
Lewiston et al., “Determination of OPT-80 and its desisobutyryl metabolite (OP-1118) in human plasma by a LC/MS/MS method”, AAPS Journal, American Association of Pharmaceutical Scientists, (2005), XP008103043.
Okumu et al., “Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of clostridium difficile associated diarrhea (CDAD)”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 204, (2004), XP008103005.
Shangle et al., “Safety and pharmacokinetics of OPT-80 in human volunteers”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, p. 1 (2004), XP008103010.
Shue et al., “Safety, tolerance, and pharmacokinetics studies of OPT-80 in healthy volunteers following single and multiple oral doses”, Antimicrobial Agents and Chemotherapy, 52(4), p. 1391-95 (2008), XP002517908.
Chemical Abstracts registyr entry 56645-60-4, Tiacumicin B, Copyright 2007, American Chemical Society, pp. 1-2.
The Condensed Chemical Dictionary, Tenth Edition, published 1981 by the Van Nostrand Reinhold Company, revised by Gessner G. Hawley, p. 35 and 835.
Polymorphism in Pharmaceutical Solids, published 1999 by Marcel Dekker Inc., ed. by Harry G. Brittain, pp. 1-2.
Pharmaceutical Dosage Forms: Tablets, vol. 2, published 1990 bu Marcel Dekker, Inc., ed. by Lieberman, Lachman, and Schwartz, pp. 462-472.
Braga, et al.: “Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism”, Chemical Communications, pp. 3635-3645, 2005.
Dean, J.: Analytical Chemistry Handbood, published 1995 by McGraw-Hill, Inc., pp. 10.23-10.26.
Hochlowski, J.E., et al.: “Tiacumicins, A Novel Complex of 18-Membered Macrolides”, J. Antibiotics, vol. XL(5), pp. 575-588, 1987.
Jain, et al.: “Polymorphism in Pharmacy”, Indian Drugs, vol. 23(6), pp. 315-329, 1986.
Credito et al., “Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species”, Antimicrobial Agents & Chemotherapy, 48(11), pp. 4430-4434 (2004).
K.L. Credito, P.C. Appelbaum, “Antianaerobic Activity of OPT 80 Compared to Other Agents,” Hershey Medical Center Department of Pathology, (poster), 44th ICAAC (Oct. 30-Nov. 2, 2004) in Chicago.
Arnone, A., et al.: “Structure Elucidation of the Macrocyclic Antibiotic Lipiarmycin”, Journal of the Chemical Society, Perkin Transactions 1, Chemical Society, pp. 1353-1359. 1987.
Caira, M. R.: “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, vol. 198, pp. 163-208, 1998.
Hochlowski, J. E., et al.: “Tiacumicins A Novel Complex of 18-Membered Macrolides II. Isolation and Structure Determination”, Journal of Antibiotics, Japan Antibiotic Research Association, vol. XL(5), pp. 575-588, 1987.
Gerber, Michael, et al.: “OPT-80, A Macrocyclie Antimicrobial Agent for the Treatment of Clostridium Difficile Infections: A Review”, Expert Opinion on Investigational Drugs, vol. 17(4), pp. 547-553, 2008.
Ansel, H.C., Allen, Jr., L.V., Popovich, N.G., Pharmaceutical Dosage Forms and Drug Delivery Systems, published by Lippincott Williams & Wilkins, pp. 23-26, 179-180 and 196 (1 (1997).
Cambridge Crystallographic Data Centre Deposition No. 100349, CCDC No. 114782 (2000).
Finegold et al. “In vitro activities of OPT-80 and comparator drugs against intestinal bacteria” Antimicrobial Agents and Chemotherapy 48(12): 4898-4902 (2004).
Gerding et al. “Clostridium difficile-associated diarrhea and colitis” Infection Control and Hospital Epidemiology 16(8):459-477 (1995).
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids” Advanced Drug Delivery Reviews 56(3):275-300 (2004).
Poduval et al. “Clostridium difficile and vancomycin-resistant enterococcus: the new nosocomial alliance” The American Journal of Gastroenterology 95(12):3513-3515 (2000).
Theriault et al. “Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity” J Antibiot (Tokyo) 40(5):567-574 (19.
Vippagunta et al. “Crystalline solids” Advanced Drug Delivery Reviews 48:3-26 (2001).
Swanson et al. “In Vitro and in Vivo Evaluation of Tiacumicins B and C against Clostridium difficile” Antimicrob. Agents Chemother. 1108-1111 (1991).
Che Tessie Mary
Chiu Yu-Hung
Ichikawa Yoshi
Romero Alex
Shue Youe-Kong
Morgan & Lewis & Bockius, LLP
Olson Eric S
Optimer Pharmaceuticals, Inc.
LandOfFree
Macrolide polymorphs, compositions comprising such... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrolide polymorphs, compositions comprising such..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrolide polymorphs, compositions comprising such... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707559